Non-natural consensus albumin binding domains

• US 9,156,887 B2
• Filed: 05/23/2013
• Issued: 10/13/2015
• Est. Priority Date: 05/25/2012
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Inventors: Jacobs, Steven
• Primary Examiner(s): Humphrey, Louise W
• Assistant Examiner(s): MARTINEZ, TARA L
• Application Number:
  US13/901,013
• Publication Number:
  US 20130316952A1
• Time in Patent Office: 873 Days
• US Class Current: 1/1
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/001 by chemical synthesis
• CPC Class Codes: C07K 14/31 from Staphylococcus (G)
• CPC Class Codes: C07K 14/315 from Streptococcus (G), e.g. Enterococci
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 2319/01 containing a localisation/targetting motif
• CPC Class Codes: C07K 2319/31 fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.

Claims

1. An isolated non-natural albumin binding domain, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:

21-34.

2. The isolated albumin binding domain of claim 1, further comprising an extension of 5 amino acids at its N-terminus.

3. The isolated albumin binding domain of claim 2, wherein the extension of 5 amino acids comprises an amino acid sequence of SEQ ID NOs:

42, 43 or 45-55.

4. The isolated albumin binding domain of claim 2, wherein the extension of 5 amino acids comprises an amino acid sequence of SEQ ID NO:

43.

5. The isolated albumin binding domain of claim 2, comprising the amino acid sequence of SEQ ID NO:

44.

6. A fusion protein comprising an albumin binding domain of claim 1 and a bioactive agent selected from the group consisting of proteins, antibodies, peptides, nucleotides, and small molecule pharmaceuticals, wherein the bioactive agent specifically binds a target molecule.

7. The fusion protein of claim 6, wherein the bioactive agent is a protein scaffold comprising a consensus sequence of a fibronectin type III (FN3) repeat protein.

8. The fusion protein of claim 7, wherein the protein scaffold comprises amino acid residues 1-90 of SEQ ID NO:

39.

9. The fusion protein of claim 7, wherein the albumin binding protein and the bioactive agent are operably linked by a linker.

10. The fusion protein of claim 9, wherein the linker comprises a Gly-Ser linker.

11. The fusion protein of claim 10, wherein the linker comprises an amino acid sequence of SEQ ID NO:

40.

12. A pharmaceutical composition comprising the fusion protein of claim 6 and at least one pharmaceutically acceptable carrier or diluent.